Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

Introduction

GlobalData’s pharmaceuticals report, “Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Doxil/Caelyx including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Doxil/Caelyx including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales estimates for 2002-2020 for Doxil/Caelyx in the seven major markets

Highlights

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
[Studien Infos ausblenden]

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 7
3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Therapy Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12
5 Doxil 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Study 15
5.4 Approval History of Doxil 15
5.5 Factors Affecting Sales of Doxil 16
5.5.1 Supply Constraint 16
5.5.2 Generics Unavailability 16
5.5.3 Strong Pipeline 16
5.6 Drug Evaluation 16
5.6.1 Drug Risk Benefit Score 16
5.6.2 Intensity of Competition 17
5.7 Sales Forecasts 17
5.7.1 Target Patient Pool of Doxil 17
5.7.2 Dosing 18
5.7.3 Market Penetration 18
5.7.4 Annual Cost of Therapy 19
5.7.5 Sales Projections of Doxil 20
6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to Take the Drug 30
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 30
6.4 Drug Sales Estimates Model 31
6.5 Contact Us 31
6.6 Disclaimer 31
6.7 Sources 32
[Inhaltsverzeichnis ausblenden]

1.1 List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030 6
Table 2: Detailed TNM Classification 13
Table 3: Study Details 15
Table 4: Approval of Doxil 15
Table 5: Drug Risk Benefit Score 16
Table 6: Doxil, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2011 19
Table 7: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20
Table 8: Doxil, Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21
Table 9: Doxil, Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020 22
Table 10: Doxil, Ovarian Cancer, France, Sales Estimates ($m), 2002-2020 23
Table 11: Doxil, Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020 24
Table 12: Doxil, Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020 25
Table 13: Doxil, Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020 26
Table 14: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Doxil 18
Figure 9: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20
Figure 10: Doxil , Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21
Figure 11: Doxil , Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020 22
Figure 12: Doxil , Ovarian Cancer, France, Sales Estimates ($m), 2002-2020 23
Figure 13: Doxil , Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020 24
Figure 14: Doxil , Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020 25
Figure 15: Doxil , Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020 26
Figure 16: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27
Figure 17: Doxil, Ovarian Cancer, Global, Sales Distribution (%), 2010 28
Figure 18: Patients Approved for the Drug 30
[Tabellenverzeichnis ausblenden]